Alessandro Lugli Selected Research

Proto-Oncogene Proteins c-raf

12/2013	Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC).
12/2011	Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
6/2009	Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer.
6/2008	RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.
1/2008	Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
5/2007	Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Lugli Research Topics

Disease

73	Neoplasms (Cancer) 01/2022 - 10/2003
59	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 08/2006
19	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2003
10	Colonic Neoplasms (Colon Cancer) 07/2021 - 09/2005
6	Adenocarcinoma 01/2016 - 10/2003
5	Carcinoma (Carcinomatosis) 07/2014 - 01/2004
4	Rectal Neoplasms (Rectal Cancer) 06/2021 - 06/2010
4	Adenoma (Adenomas) 04/2016 - 10/2003
4	Lymphatic Metastasis 01/2016 - 10/2010
4	Microsatellite Instability 01/2012 - 06/2008
3	Disease Progression 01/2019 - 01/2014
2	Polyps 04/2016 - 01/2016
2	Inflammation (Inflammations) 01/2016 - 03/2010
2	B-Cell Lymphoma (Lymphoma, B Cell) 12/2011 - 10/2010
2	Prostatic Neoplasms (Prostate Cancer) 12/2009 - 09/2004
2	Hodgkin Disease (Hodgkin's Disease) 11/2003 - 02/2003
1	Turcot syndrome 01/2022
1	Gastritis 07/2021
1	Cardiac Arrhythmias (Arrythmia) 07/2021
1	Pyoderma 02/2018
1	Erythema Nodosum 02/2018
1	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2018
1	Monosomy 01/2016

Drug/Important Bio-Agent (IBA)

25	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2004
17	Biomarkers (Surrogate Marker)IBA 07/2021 - 10/2007
10	Indicators and Reagents (Reagents)IBA 07/2021 - 09/2005
10	Keratins (Keratin)IBA 01/2019 - 10/2010
7	ErbB Receptors (EGF Receptor)IBA 12/2011 - 10/2007
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 09/2006
6	Proto-Oncogene Proteins c-rafIBA 12/2013 - 05/2007
5	ParaffinIBA 07/2021 - 07/2010
5	Hyaluronic Acid (Hyaluronan)IBA 07/2021 - 10/2006
5	Phosphotransferases (Kinase)IBA 01/2019 - 03/2007
5	Calcibiotic Root Canal SealerIBA 01/2016 - 05/2007
5	Complement System Proteins (Complement)IBA 05/2015 - 12/2009
5	Cadherins (E-Cadherin)IBA 01/2015 - 01/2010
5	Peptide Hydrolases (Proteases)FDA Link 12/2011 - 09/2006
4	Tumor Biomarkers (Tumor Markers)IBA 06/2008 - 09/2006
3	Formaldehyde (Formol)FDA Link 07/2021 - 11/2014
3	Biological ProductsIBA 01/2021 - 01/2004
3	Eosine Yellowish-(YS) (Eosin)IBA 01/2019 - 10/2012
3	LigandsIBA 01/2019 - 03/2010
3	MethyltransferasesIBA 01/2018 - 01/2012
3	Epithelial Cell Adhesion MoleculeIBA 01/2016 - 01/2004
3	Matrix Metalloproteinase 7 (Matrilysin)IBA 12/2011 - 08/2010
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2011 - 08/2006
3	beta CateninIBA 08/2010 - 10/2007
3	Mitogen-Activated Protein KinasesIBA 05/2007 - 08/2006
2	ArsenicIBA 07/2021 - 03/2011
2	AntibodiesIBA 01/2019 - 03/2013
2	Hematoxylin (Haematoxylon)IBA 01/2019 - 05/2015
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2012
2	theasinensin AIBA 01/2018 - 04/2016
2	hyaluronan-mediated motility receptorIBA 09/2017 - 11/2015
2	RNA (Ribonucleic Acid)IBA 09/2017 - 01/2016
2	CytokinesIBA 11/2016 - 07/2014
2	RNA-Binding Proteins (RNA-Binding Protein)IBA 08/2015 - 12/2010
2	CDX2 Transcription FactorIBA 05/2014 - 12/2011
2	AntigensIBA 01/2014 - 12/2009
2	EphB2 ReceptorIBA 12/2011 - 09/2005
2	Ephrin-B2 (Ephrin B2)IBA 12/2011 - 06/2008
2	CateninsIBA 12/2011 - 10/2010
2	Tryptases (Tryptase)IBA 09/2011 - 12/2010
2	Granzymes (Granzyme)IBA 09/2011 - 12/2009
2	Urokinase Plasminogen Activator ReceptorsIBA 01/2010 - 06/2009
2	Imatinib Mesylate (Gleevec)FDA Link 01/2005 - 11/2004
1	MucinsIBA 01/2022
1	VimentinIBA 01/2019
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2019
1	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 01/2019
1	Bevacizumab (Avastin)FDA Link 01/2019
1	Cetuximab (Erbitux)FDA Link 01/2019
1	Capecitabine (Xeloda)FDA Link 01/2019
1	Cathepsin BIBA 01/2019
1	Caspase 3 (Caspase-3)IBA 02/2018
1	trichostatin A (A 300)IBA 01/2018
1	Histones (Histone)IBA 01/2018
1	LMK-235IBA 01/2018
1	Histone Deacetylase InhibitorsIBA 01/2018
1	Decitabine FDA Link 01/2018
1	InterferonsIBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Fluorouracil (Carac)FDA LinkGeneric 01/2017
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2017
1	DNA Polymerase IIIBA 11/2016
1	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 04/2016
1	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 01/2016
1	TensinsIBA 01/2016
1	Interleukin-33IBA 01/2016
1	InterleukinsIBA 01/2016
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2016
1	Death-Associated Protein KinasesIBA 11/2015
1	tapasinIBA 08/2015
1	I-antigenIBA 08/2015

Therapy/Procedure

18	Therapeutics 07/2021 - 01/2004
3	Adjuvant Chemotherapy 07/2021 - 06/2008
3	Neoadjuvant Therapy 06/2021 - 01/2012
2	Drug Therapy (Chemotherapy) 11/2020 - 01/2017
2	Immunotherapy 11/2020 - 01/2018
2	Lasers (Laser) 01/2016 - 01/2015